Azel 40mg capsule

Azel 40mg capsule is an anti-cancer medication. The medicine is used in the treatment of advanced prostate cancer in adults. It works by blocking the action of testosterone hormone which is responsible for the growth of cancer cells In the body. The medicine active ingredient is Enzalutamide which belongs to the group of androgen receptor inhibitor that prevents the stimulation and multiplication of prostate cancer cells. It helps to slow down the disease progression and promote cancer cell growth. Doctor recommended the exact dose and duration of the treatment. Strictly follow the prescribed dosage to avoid complication during the treatment.

Advanced prostate cancer

Azel 40mg capsule cause some side effects which are harmful during the treatment. Kindly consult the doctor before starting using the medication. Common ones include:
● Fatigue and weakness
● Hot flushes
● Muscle pain
● Joint discomfort
● Headaches
● Dry skin
● Diarrhea
● Nausea
● High blood pressure
● Memory difficulties
● Upper respiratory tract infections

Azel 40mg capsule should be taken under doctor prescription to know the exact dosage and duration. Most of the healthcare professionals recommend taking the medicine with or without food, as food does not affect its absorption and effectiveness. Always follow the doctor instructions regarding the treatment plan to ensure safety and effectiveness.

Azel 40mg capsule is a targeted therapy. It is directly attack on testosterone hormone which is responsible for the growth of abnormal cells in the body. The medication does not damage the healthy cells in response to stop the tumor growth. This mechanism allows the body to maintain normal function and reduces the risk of side effects.

• Beer, T. M., Armstrong, A. J., Rathkopf, D. E., Loriot, Y., Sternberg, C. N., Higano, C. S., ... & Tombal, B. (2014). Enzalutamide in metastatic prostate cancer before chemotherapy. New England Journal of Medicine, 371(5), 424-433.
• Davis, I. D., Martin, A. J., Stockler, M. R., Begbie, S., Chi, K. N., Chowdhury, S., ... & Sweeney, C. J. (2019). Enzalutamide with standard first-line therapy in metastatic prostate cancer. New England Journal of Medicine, 381(2), 121-131.
• Claessens, F., Helsen, C., Prekovic, S., Van den Broeck, T., Spans, L., Van Poppel, H., & Joniau, S. (2014). Emerging mechanisms of enzalutamide resistance in prostate cancer. Nature reviews urology, 11(12), 712-716.
• Scher, H. I., Fizazi, K., Saad, F., Taplin, M. E., Sternberg, C. N., Miller, K., ... & de Bono, J. S. (2012). Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine, 367(13), 1187-1197.
• Gibbons, J. A., Ouatas, T., Krauwinkel, W., Ohtsu, Y., van der Walt, J. S., Beddo, V., ... & Mordenti, J. (2015). Clinical pharmacokinetic studies of enzalutamide. Clinical Pharmacokinetics, 54(10), 1043-1055.